NASDAQ · Biotechnology

LAVA Therapeutics N.V. (LVTX) Stock

$1.74 -3.87% NASDAQ: LVTX Healthcare

LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer.

Valuation

MetricValue
Price$1.74
Market Cap$45.77M
P/E Ratio-2.42
P/B Ratio3.69
P/S Ratio3.81
EPS (TTM)$-0.94
52-Week High$2.00
52-Week Low$0.85
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-99.17%
ROA-37.19%
ROCE-47.04%
Gross Margin-250.00%
Operating Margin-250.00%
Net Margin-208.33%
Debt/Equity0.18
Current Ratio12.27

Annual Financials (USD)

Metric20202021202220232024
Revenue$4.0M$5.0M$19.0M$7.0M$12.0M
Operating Profit$-15.0M$-44.0M$-35.0M$-43.0M$-30.0M
Net Profit$-16.0M$-42.0M$-32.0M$-42.0M$-25.0M
EPS$-39.90$-2.14$-1.23$-1.57$-0.94
Op Margin-391.6%-815.2%-179.7%-641.1%-247.8%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$20.0M$139.0M$143.0M$102.0M$81.0M
Total Liabilities$13.0M$21.0M$57.0M$51.0M$53.0M
Cash$16.0M$91.0M$100.0M$44.0M$35.0M
Borrowings$4.0M$5.0M$5.0M$6.0M$5.0M

Latest News

CPSC Posts Product Safety Warning to its Web Site PR Newswire · Jul 22, 2026 EMIRATES ADDS LIKE NASTYA TO ITS AWARD-WINNING ICE INFLIGHT ENTERTAINMENT SYSTEM PR Newswire · Jul 22, 2026 Mexico, RFK Jr., Taylor Farms weigh in on cyclospora outbreak USA TODAY · Jul 22, 2026 Packaging Corporation of America (NYSE:PKG) Posts Q2 CY2026 Sales In Line With Estimates StockStory · Jul 22, 2026 Historic Markets, Bold Momentum: Publicly Traded ELEKTROS (OTC Pink:ELEK) Advances EV Infrastructure While Shares Gain 23.40% ACCESS Newswire · Jul 22, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-9.0M$-29.0M$4.0M$-40.0M$-20.0M
Investing Cash Flow$-1.0M$-44.0M$9.0M$-18.0M$12.0M
Financing Cash Flow$-5.0M$-6.0M$0$0$0
Net Cash Flow$8.0M$75.0M$9.0M$-56.0M$-9.0M
Free Cash Flow$-10.0M$-29.0M$3.0M$-41.0M$-20.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.18
EV / EBITDA0.21
FCF Yield-66.12%
Quick Ratio12.27
Interest Coverage-173.88
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATNM $0.80 +1.32% -1.07 $25.02M 0.00%
CALCCalciMedica, Inc. $0.73 -3.82% -0.57 $11.55M 0.00%
CELUCelularity Inc. $0.75 +0.13% -0.20 $21.74M 0.00%
ELUT $0.86 -5.33% -1.24 $37.88M 0.00%
LTRN $2.63 -0.75% -2.02 $33.56M 0.00%

About LAVA Therapeutics N.V.

LAVA Therapeutics N.V. is an immuno-oncology firm, currently in the clinical development phase, dedicated to pioneering novel therapies for cancer. Utilizing its proprietary Gammabody platform, the company engineers innovative bispecific antibodies. These antibodies are specifically designed to engage and harness the potent and precise capabilities of gamma delta T cells, aiming to stimulate a robust anti-tumor immune response and ultimately enhance outcomes for individuals battling cancer. Key compounds in its clinical pipeline include LAVA-051, currently undergoing Phase 1/2a trials for various hematologic malignancies such as chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. Another front-runner, LAVA-1207, is also in Phase 1/2a clinical studies, targeting metastatic castration-resistant prostate cancer. Furthermore, LAVA Therapeutics is advancing additional Gammabody candidates: LAVA-1223, an investigational treatment for specific solid tumors that targets the epidermal growth factor receptor (EGFR), and preclinical assets LAVA-1266 and LAVA-1278, intended for a range of blood cancers. The company has also forged a research collaboration and licensing partnership with Janssen Biotech, Inc. This alliance focuses on the potential discovery and development of multi-specific antibody therapies aimed at a particular target across diverse therapeutic applications. Established in 2016, LAVA Therapeutics N.V. operates from its headquarters in Utrecht, the Netherlands.

LAVA Therapeutics N.V. is headquartered in NL.

LAVA Therapeutics N.V. (LVTX) stock trades at $1.74 with a market capitalization of $45.77M. The stock is valued at a price-to-earnings (P/E) ratio of -2.42, price-to-book of 3.69, price-to-sales of 3.81. Over the past 52 weeks the stock has ranged between $0.85 and $2.00, and currently trades 13.0% below its 52-week high.

On profitability, LAVA Therapeutics N.V. generates a return on equity (ROE) of -99.17%, return on capital employed of -47.04%, an operating margin of -250.00%, a net profit margin of -208.33%.

Official website: www.lavatherapeutics.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides